For most people, a positive genetic test is the beginning of a long, anxious wait. For Jeff Vierstra, it was something closer to a death sentence — one he’d already watched claim his mother and both of his sisters.
Vierstra, a scientist by training, carries a rare mutation in the FUS gene — the same mutation that killed his mother, his sisters Erin and Leigh, and three of his aunts, all from complications of ALS, the brutal neurodegenerative disease that strips away movement, speech, and eventually the ability to breathe. Now, in an almost cinematic twist, his scientific background has landed him at the center of an experimental treatment that might actually stop the disease before it starts.
A Family Haunted by One Gene
ALS — amyotrophic lateral sclerosis — affects an estimated 35,000 people in the United States at any given time, slowly destroying the motor neurons that control nearly every voluntary movement in the body. About 10 to 15 percent of cases are genetic, with two-thirds of those running in families across multiple generations. For the Vierstra family, that statistic isn’t abstract. It’s a obituary written over and over again.
Jeff’s mother died just nine months after her first ALS symptoms appeared. That’s the particular cruelty of the FUS mutation — it doesn’t linger. It moves fast and leaves little room for anything but grief. His sisters followed. “Living with that sort of like cloud over you is like mentally and emotionally like really difficult,” Vierstra said, in the kind of quiet understatement that only makes the weight of it hit harder.
When Jeff tested positive for the FUS mutation himself, doctors weren’t just concerned — they were alarmed. Dr. Neil Shneider, a neurologist at Columbia University, didn’t mince words about what the results suggested. “We thought this meant that this was an early sign of disease onset and that he was at risk for developing full blown disease,” Dr. Shneider noted.
The Drug That Silences a Deadly Gene
Here’s where the story takes a turn that feels almost too neat — except that it’s real, and people’s lives depend on it. Shneider had been quietly working on a potential solution. His team’s mouse studies showed that a drug developed by Ionis Pharmaceuticals, called ulefnersen, could effectively silence the FUS gene — reducing the levels of the toxic protein it produces in both the brain and spinal cord, slowing or delaying the degeneration of motor neurons before symptoms even appear.
The science is elegant in the way that only the most desperate problems sometimes produce. Ulefnersen works as an antisense oligonucleotide — essentially a molecular switch that tells the body to stop producing the harmful FUS protein. In animal models, it delayed motor neuron damage significantly. Whether it can do the same in humans is still being studied, but the early signals were compelling enough that the FDA granted expanded access — allowing patients like Jeff to receive the treatment outside of a formal clinical trial.
That pathway wasn’t automatic. It required a coordinated push from Columbia, Ionis, and partners including Charles River Laboratories, whose scientists helped fast-track the regulatory process. “These are tough issues,” said Dr. Lauren Black, Distinguished Scientist with Charles River’s Scientific Advisory Services — a line that, in context, carries more weight than it might seem. Getting experimental treatments to dying patients quickly, without cutting corners on safety, is genuinely hard. The science has to be right, and the paperwork has to move.
A Scientist in the Patient’s Chair
What makes Jeff’s story particularly striking is that he didn’t stumble into this treatment by accident. He was already embedded in the world of biomedical research when he first learned about the work being done on ALS. “Some of the scientists gave this amazing talk about the work they were doing in ALS,” Jeff recalled. That talk, in a very real sense, may have saved his life — or at least bought him time.
Still, the situation isn’t without its profound uncertainties. Vierstra is receiving a drug that’s never been approved, for a disease he technically doesn’t yet have, based on a genetic marker that has — so far — been a reliable predictor of death in his family. The treatment is designed to interrupt that trajectory, but no one can say with certainty that it will. That’s the nature of expanded access — it’s hope with paperwork, not a guarantee.
Cases like Jeff’s and others carrying the same FUS mutation — including a patient named Jaci, whose story helped galvanize the push for faster FDA access — have become something of a proving ground for what personalized, pre-symptomatic ALS treatment might eventually look like. The FUS mutation is rare even within ALS, and patients who carry it typically face death within a year of diagnosis. That urgency is part of what drove researchers and regulators to move as quickly as they did.
What It Means Beyond One Family
The broader implications aren’t lost on anyone paying attention. If a drug can be designed to silence a specific genetic mutation before it causes disease — and if the regulatory system can be nimble enough to get it to patients in time — that’s a model worth watching. ALS research has historically moved at a pace that felt cruelly slow relative to how fast the disease itself progresses. This case suggests a different approach might be possible.
That said, FUS-related ALS represents only a small fraction of cases. Most people living with the disease don’t have a neatly identifiable single-gene cause, and they won’t benefit directly from this particular drug. The science of neurodegeneration remains staggeringly complex, and for every Jeff Vierstra — a scientist who happened to be in the right room at the right time — there are thousands of patients with far fewer options.
For now, though, Jeff Vierstra is alive, being treated, and watching the data accumulate in real time — a man who spent years studying biology, only to become one of its most consequential test cases. The cloud, he said, is still there. But for the first time in his family’s history, someone beneath it is fighting back with more than just hope.
